R
RVU
vs
W
WIG20
Over the past 12 months, RVU has underperformed WIG20, delivering a return of -4% compared to the WIG20's +28% growth.
Stocks Performance
RVU vs WIG20
Performance Gap
RVU vs WIG20
Performance By Year
RVU vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.